Go Pro

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$1,185.72
-0.2%
$1,103.63
$623.78
$1,249.45
$1.12T0.512.87 million shs2.07 million shs
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$123.93
+0.3%
$119.12
$76.66
$130.29
$305.12B0.1910.67 million shs5.19 million shs
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$49.28
-0.4%
$45.71
$35.12
$71.79
$220.93B0.7710.27 million shs7.41 million shs
Novartis AG stock logo
NVS
Novartis
$153.35
-0.5%
$150.96
$112.34
$170.46
$293.95B0.452.05 million shs1.18 million shs
Options Trading Made Easy - Download Now Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
-0.28%-1.26%+4.28%+28.49%+49.46%
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
+0.17%-2.25%+4.10%+3.33%+48.69%
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
-0.42%0.00%+12.25%+25.30%-28.51%
Novartis AG stock logo
NVS
Novartis
-0.46%-1.32%+0.21%-0.04%+26.81%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$1,185.72
-0.2%
$1,103.63
$623.78
$1,249.45
$1.12T0.512.87 million shs2.07 million shs
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$123.93
+0.3%
$119.12
$76.66
$130.29
$305.12B0.1910.67 million shs5.19 million shs
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$49.28
-0.4%
$45.71
$35.12
$71.79
$220.93B0.7710.27 million shs7.41 million shs
Novartis AG stock logo
NVS
Novartis
$153.35
-0.5%
$150.96
$112.34
$170.46
$293.95B0.452.05 million shs1.18 million shs
Options Trading Made Easy - Download Now Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
-0.28%-1.26%+4.28%+28.49%+49.46%
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
+0.17%-2.25%+4.10%+3.33%+48.69%
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
-0.42%0.00%+12.25%+25.30%-28.51%
Novartis AG stock logo
NVS
Novartis
-0.46%-1.32%+0.21%-0.04%+26.81%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
2.87
Moderate Buy$1,268.787.01% Upside
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
2.70
Moderate Buy$133.948.08% Upside
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
2.17
Hold$65.5633.04% Upside
Novartis AG stock logo
NVS
Novartis
2.31
Hold$141.20-7.92% Downside

Current Analyst Ratings Breakdown

Latest NVS, LLY, MRK, and NVO Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/13/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Boost Price TargetBuy$1,250.00 ➝ $1,425.00
7/13/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Boost Price TargetBuy$1,235.00 ➝ $1,273.00
7/13/2026
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
Boost Price TargetOverweight$135.00 ➝ $140.00
7/13/2026
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
Boost Price TargetOutperform$135.00 ➝ $142.00
7/13/2026
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
Boost Price TargetBuy$140.00 ➝ $145.00
7/10/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Boost Price TargetBuy$1,251.00 ➝ $1,334.00
7/9/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Set Price Target$1,370.00
7/9/2026
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
Boost Price TargetEqual Weight$112.00 ➝ $113.00
7/8/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Boost Price TargetBuy$1,281.00 ➝ $1,370.00
7/8/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Boost Price TargetOverweight$1,344.00 ➝ $1,347.00
7/8/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Boost Price TargetOutperform$1,250.00 ➝ $1,500.00
(Data available from 7/14/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$65.18B17.13$25.08 per share47.28$28.07 per share42.24
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$65.01B4.71$11.46 per share10.81$21.22 per share5.84
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$46.80B4.70$4.67 per share10.56$6.58 per share7.49
Novartis AG stock logo
NVS
Novartis
$54.53B5.37$10.69 per share14.34$22.04 per share6.96
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$20.64B$28.1542.1225.951.4734.98%105.77%23.76%8/5/2026 (Estimated)
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$18.25B$3.5534.9112.522.6513.59%27.55%10.73%8/4/2026 (Estimated)
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$15.51B$4.2611.5715.074.5137.23%63.31%22.19%8/5/2026 (Estimated)
Novartis AG stock logo
NVS
Novartis
$13.98B$6.9821.9715.762.6524.87%38.82%15.16%7/21/2026 (Estimated)

Latest NVS, LLY, MRK, and NVO Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/5/2026Q2 2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$8.82N/AN/AN/A$20.53 billionN/A
8/5/2026Q2 2026
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$0.82N/AN/AN/A$10.99 billionN/A
8/4/2026Q2 2026
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$2.15N/AN/AN/A$16.40 billionN/A
7/21/2026Q2 2026
Novartis AG stock logo
NVS
Novartis
$2.17N/AN/AN/A$14.16 billionN/A
5/6/2026Q1 2026
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$0.87$1.04+$0.17$1.69$10.86 billion$10.85 billion
4/30/2026Q1 2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$6.97$8.55+$1.58$8.26$17.82 billion$19.80 billion
4/30/2026Q1 2026
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
-$1.47-$1.28+$0.19-$1.72$15.85 billion$16.29 billion
4/27/2026Q1 2026
Novartis AG stock logo
NVS
Novartis
$2.11$1.99-$0.12$1.65$13.44 billion$13.52 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$6.920.58%+15.18%24.58%11 Years
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$3.402.74%+5.75%95.77%14 Years
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$1.753.55%+21.74%41.08%N/A
Novartis AG stock logo
NVS
Novartis
$3.082.01%+5.28%44.13%N/A

Latest NVS, LLY, MRK, and NVO Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
6/22/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
quarterly$1.730.63%8/14/20268/14/20269/10/2026
5/26/2026
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
quarterly$0.852.96%6/15/20266/15/20267/8/2026
5/4/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
quarterly$1.730.69%5/15/20265/15/20266/10/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
1.26
1.50
1.10
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
1.02
1.30
1.06
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
0.59
0.79
0.56
Novartis AG stock logo
NVS
Novartis
0.96
0.85
0.65

Institutional Ownership

CompanyInstitutional Ownership
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
82.53%
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
76.07%
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
11.54%
Novartis AG stock logo
NVS
Novartis
13.12%

Insider Ownership

CompanyInsider Ownership
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
0.14%
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
0.17%
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
0.07%
Novartis AG stock logo
NVS
Novartis
0.01%
CompanyEmployeesShares OutstandingFree FloatOptionable
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
50,000941.74 million940.42 millionOptionable
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
75,0002.47 billion2.47 billionOptionable
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
69,5054.47 billion4.46 billionOptionable
Novartis AG stock logo
NVS
Novartis
75,2671.91 billion1.91 billionOptionable

Recent News About These Companies

Novartis (NVS) Projected to Announce Earnings on Tuesday
Midwest Trust Co Lowers Stake in Novartis AG $NVS
Why Novartis (NVS) Stock Fell Today

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Eli Lilly and Company stock logo

Eli Lilly and Company NYSE:LLY

$1,185.71 -2.87 (-0.24%)
Closing price 07/13/2026 03:59 PM Eastern
Extended Trading
$1,177.28 -8.44 (-0.71%)
As of 05:08 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Merck & Co., Inc. stock logo

Merck & Co., Inc. NYSE:MRK

$123.93 +0.39 (+0.32%)
Closing price 07/13/2026 03:59 PM Eastern
Extended Trading
$124.19 +0.26 (+0.21%)
As of 05:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Novo Nordisk A/S stock logo

Novo Nordisk A/S NYSE:NVO

$49.28 -0.20 (-0.40%)
Closing price 07/13/2026 03:59 PM Eastern
Extended Trading
$49.08 -0.20 (-0.41%)
As of 05:09 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with Aspen Pharmaceuticals to produce insulin products; and with Korro Bio, Inc. for the discovery and development of new genetic medicines to treat cardiometabolic diseases. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

Novartis stock logo

Novartis NYSE:NVS

$153.35 -0.70 (-0.45%)
Closing price 07/13/2026 03:59 PM Eastern
Extended Trading
$151.63 -1.72 (-1.12%)
As of 05:01 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn Health for the development and commercialization of Ekiva, a digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.